Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.69 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20169329 | 0.89 | DGAT1 (0.55) | DGAT1MMP13ENPP3ENPP1KDM4E | |
| SCHEMBL9940353 | 0.88 | DGAT1 (0.60) | DGAT1 | |
| SCHEMBL9940501 | 0.86 | DGAT1 (0.72) | DGAT1 | |
| SCHEMBL16787712 | 0.84 | DGAT1 (0.55) | DGAT1 | |
| SCHEMBL15282965 | 0.84 | DGAT1 (0.61) | DGAT1 | |
| SCHEMBL16661314 | 0.83 | DGAT1 (0.65) | DGAT1 | |
| SCHEMBL16660945 | 0.83 | DGAT1 (0.58) | DGAT1ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL20428678 | 0.82 | DGAT1 (0.57) | DGAT1ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL21064872 | 0.82 | DGAT1 (0.57) | DGAT1ENPP3ENPP1KDM4EALDH1A1 | |
| SCHEMBL16787677 | 0.82 | DGAT1 (0.73) | DGAT1ENPP3ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308636-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-04 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975871-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-9546155-B2 | Aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-17 | — | — | US | disclosed |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-09-22 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-9302996-B2 | Continuous arycyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2862856-A1 | AROMATIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2651915-A1 | CONTINUOUS ARYCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2012081736-A1 | CONTINUOUS ARYCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DGAT1 1688/4885MMP13 3639/4885ENPP3 4854/4885 |
| US-10308636-B2 | Aromatic heterocyclic compound | GPR119, NR0B1, BET1 | DGAT1 1688/4885MMP13 3639/4885ENPP3 4854/4885 |
| US-20130261128-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885MMP13 1857/4885ENPP3 2695/4885 |
| US-20170050950-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | DGAT1 1688/4885MMP13 3639/4885ENPP3 4854/4885 |
| US-20160272614-A1 | CONTINUOUS ARYCYCLIC COMPOUND | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885MMP13 1857/4885ENPP3 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.